RARA CRAFT DATABASE for FDA Medical Devices
510(k)K232761

FDA DEVICE FACTS

ProNephro AKI™ (NGAL)

Bioporto Diagnostic, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEDecember 7, 2023PRODUCT CODEPIG

Indications for use

8.1. Indications for Use Immunoassay for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine. Determination of NGAL is intended to be used in conjunction with clinical evaluation in pediatric patients (≥ 3 months to < 22 years) without underlying kidney disease admitted to the intensive care unit (ICU) for the management of cardiovascular or respiratory compromise or who have had a solid organ or bone marrow transplant. ProNephro AKI™ (NGAL) is intended to be used in the first 24 hours of ICU admission. In patients with low SCr levels, indicative of no acute kidney injury (AKI) or AKI Stage 1, the test can be used as an aid to identify patients at risk to develop moderate to severe AKI (Stage 2/3) 48 to 72 hours after the assessment. In patients with an elevated SCr level, indicative of Stage 2/3 AKI, the test can be used as an aid to identify patients at risk to have persistent moderate to severe AKI (Stage 2/3) 48 to 72 hours after the assessment. The particle-enhanced turbidimetric immunoassay is intended for use on the Roche cobas® c 501 clinical chemistry analyzer. 8.2. Special Conditions for Use Statement(s) For in Vitro Diagnostics Use and Rx only Warnings and Precautions for the Assay

• This kit should only be used by qualified laboratory staff.

• Do not shake the reagents.

• Use only clean containers if transferring reagents.

• Do not pour reagents back into the original containers once transferred.

• All specimens used in this test should be considered potentially infectious, and as such be treated with standard precautions.

• Powder-free gloves should be worn. Avoid direct skin contact. Should reagents come into contact with the skin, eyes or mouth, flush with plenty of water. Seek medical advice if any symptom is observed or when it is considered necessary. P roNephro AKI™ (NGAL)

• Reagents contain preservatives with 2-methyl-2H isothiazol-3-one (MIT) which may cause an allergic skin reaction. For more information, please refer to the safety data sheet.

• Do not switch caps on reagent containers as it may cause contamination or mix-up.

• Place calibrators in the correct order onto the instrument to ensure a correct calibration curve.

• Do not use reagents after the expiration date on the labels.

• Reagents with different lot numbers should not be mixed.

• All solutions and samples must be handled carefully and disposed of in accordance with national and local regulations. 8.3. Special Instrument Requirements Roche cobas® c 501 clinical chemistry analyzer P roNephro AKI™ (NGAL)

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 17, 2026